Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

31 results about "CD5" patented technology

CD5 is a cluster of differentiation expressed on the surface of T cells (various species) and in a subset of murine B cells known as B-1a. The expression of this receptor in human B cells has been a controversial topic and up to date there is no consensus regarding the role of this receptor as a marker of human B cells. B-1 cells have limited diversity of their B-cell receptor due to their lack of the enzyme terminal deoxynucleotidyl transferase (TdT) and are potentially self-reactive. CD5 serves to mitigate activating signals from the BCR so that the B-1 cells can only be activated by very strong stimuli (such as bacterial proteins) and not by normal tissue proteins. CD5 was used as a T-cell marker until monoclonal antibodies against CD3 were developed.

Combined reagent for detecting acute myelocytic leukemia cells and system thereof

ActiveCN109655616AWide coverageThere is no problem of reciprocal inhibition of expressionMaterial analysisCD33CD15
The invention relates to a combined reagent for detecting acute myelocytic leukemia cells and a system thereof, wherein the combined reagent and the system thereof belong to the field of medical technology. The combined reagent comprises at least one selected from the following antibody combinations: a first antibody combination which comprises CD38, CD13, CD34, CD117, CD33, CD19, HLA-DR and CD45antibodies; a second antibody combination which comprises CD38, CD64, CD34, CD123, CD56, CD14, HLA-DR and CD45 antibodies; and a third antibody combination which comprises CD38, CD7, CD34, CD5, CD11b,CD15 and CD45 antibodies. The antibody combinations of the invention cover the expression marks of three systems of granulocyte, single cell and lymphocyte. A normal antibody expression mode is established. Tumor cells can be identified maximally. Furthermore, through a large number of experiment data, the antibodies in each combination have no problem of mutual expression inhibition. FurthermoreAML-MRD can be comprehensively and quickly detected with high sensitivity through multi-parameter flow type cell analysis.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT

Chimeric antigen receptors (CAR) targeting hematologic malignancies, compositions and methods of use thereof

The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.
Owner:ICELL GENE THERAPEUTICS LLC +5

Anti-CD5 protein monoclonal antibody as well as cell strain, preparation method and application thereof

The invention relates to a monoclonal antibody capable of recognizing a human CD5 antigen, a secretory cell strain, a preparation method of the monoclonal antibody and application in immunodetection. According to the technical scheme, amino acids from the 398th site to the 495th site of the C terminal of the CD5 protein are selected as antigen peptides, codon optimization is carried out, a gene segment suitable for being expressed in escherichia coli BL21 is formed, and the finally obtained recombinant protein comprises a CD5 protein segment and a histidine protein tag. A mouse is immunized by the recombinant protein, and the mouse hybridoma cell strain 11H3 capable of efficiently secreting the anti-CD5 protein monoclonal antibody and the anti-CD5 protein monoclonal antibody secreted by the cell strain are obtained through cell fusion, screening and subcloning. The antibody obtained by the scheme has high specificity and sensitivity, can specifically recognize cells expressing CD5 protein, and is suitable for immunological detection, especially immunohistochemical detection.
Owner:FUZHOU MAIXIN BIOTECH CO LTD

Combined reagent and system for evaluating chronic lymphocytic leukemia prognosis

The invention relates to a combined reagent and a system for evaluating chronic lymphocytic leukemia prognosis, and belongs to the field of medical technology detection. The combined reagent comprisesat least one of the following antibody combinations: an antibody combination 1 including CD5, IgG1, CD3, CD 19 and CD45 antibodies, an antibody combination 2 including CD5, ZAP70, CD3, CD19 and CD45antibodies, and an antibody combination 3 including CD38, CD49d, CD19, CD5 and CD45 antibodies. In the above antibody combinations which aim at CLL (Chronic Lymphocytic Leukemia), the expression of ZAP70, CD38 and CD49d has a great value on an aspect of prognosis evaluation, ZAP70 is accurate, bus since an intracellular dyeing and gating technology restricts clinical application, and the combinedreagent solves the problem to a maximum degree. In addition, two indexes are increased, markers are combined, and chronic lymphocytic leukemia prognosis can be more comprehensively evaluated.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT

Soluble protein cd5 or cd6 for the treatment of cancer or tumor or for use as an adjuvant

The present invention discloses soluble isoforms of CD5 and CD6, which are scavenger-like lymphocyte receptors, for use in the prophylaxis or therapy of disorders or in therapeutic interventions, which would benefit from an exacerbated immune response to either endogenous or exogenous antigens, resulting from a decrease in lymphocyte subpopulations with regulatory functions and / or increase in lymphocyte subpopulations with effector functions. Special disorders are cell growth disorders, and chronic infections of bacterial, viral, fungal or parasitic origin. The invention also provides animal models for the study and the prophylaxis / treatment of autoimmune diseases, cancer, and chronic infections.
Owner:FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA +2

Oligopeptide molecules, and preparation methods and applications thereof

Disclosed are oligopeptide molecules, preparation methods therefor and uses thereof. Said oligopeptides comprise CD1、CD2、CD3、CD4、CD5、CD6、CD7、CD8、CD9、CD10、CD11、CD12、CD13 and CD14. The amino acid sequences are shown in SEQ ID NO: 1-14 respectively. The oligopeptides can be prepared by synthesis, extraction or genetic engineering etc. Also disclosed are the uses of said oligopeptides in the preparation of anti-inflammatory and analgesic, wound healing and immunity enhancing drugs.
Owner:陈光健

Kit for rapidly detecting peripheral T cell lymphoma and use method thereof

PendingCN112986565AQuick checkQuick quantityMaterial analysisCD5CD16
The invention belongs to the field of immunological detection, and relates to a kit, in particular to a kit for rapidly detecting peripheral T cell lymphoma and a use method of the kit. The kit comprises a reagent I and a reagent II, the reagent I comprises two groups of monoclonal antibody mixtures, and the first group of monoclonal antibody mixture comprises TRBC1, CD2, CD3, CD5, CD7, CD16, CD56, CD57 and CD45; the second group of monoclonal antibody mixture comprises the following components: TRBC1, TCR-gamma delta, CD3, CD8, CD4, CD7 and CD45; and the reagent II is hemolysin. The kit provided by the invention realizes the rapid and accurate detection of the peripheral T cell lymphoma (PTCL), is simple and convenient, greatly reduces the requirement on the sample size, and reduces the burden of a patient.
Owner:河南凯普瑞生物技术有限公司

CAR-NK cell as well as preparation method and application thereof

The invention relates to a CAR-NK cell as well as a preparation method and application thereof. The invention firstly provides a bispecific chimeric antigen receptor targeting BCMA and CD5, the bispecific chimeric antigen receptor has the following structure: S-BCMA scFv-CD5scFv-H-TM-CF-CD3zeta, the BCMA scFv is a BCMA antigen binding domain, the BCMA scFv-CD5scFv-H-TM-CF-CD3zeta is a BCMA antigen binding domain, and the BCMA The CD5 scFv is a CD5 antigen binding domain; s is a signal peptide; h is a hinge area; tM is a transmembrane area; cF is a costimulatory factor; cD3zeta is a CD3zeta intracellular signal domain, the chimeric antigen receptor can be combined with two anti-tumor targets, namely BCMA and CD5 at the same time, and the targeting property and effectiveness can be remarkably improved; by knockout of immune checkpoint inhibitor genes in NK cells, it is possible to prevent tumor cells from triggering immune escape through specific binding with related immune checkpoint inhibitor sites, and experimental data proves that CTLA4 is selected as a knockout immune checkpoint and has more advantages compared with other immune checkpoint genes such as PD-1, Tim-3 and LAG-3. The chimeric antigen receptor is introduced into an NK cell to prepare a CAR-NK cell, and the CAR-NK cell can inhibit leukemia cell proliferation, regulate expression levels of cell factors such as IL-6, IL-12 and IFN-gamma, inhibit growth of tumors in an animal model and play a synergistic anti-tumor role.
Owner:JIANGSU MOBILI BIOTECH CO LTD

Use of cd2/5/7 knock-out Anti-cd2/5/7 chimeric antigen receptor t cells against t cell lymphomas and leukemias

The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells, wherein CD2, CD5, or CD7 has been knocked-out.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias

ActiveUS20220073639A1Unlikely can be integratedAnimal cellsPeptide/protein ingredientsAntigen receptorCD5
The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Human T lymphoblastic leukemia/lymphoma cell strain and application thereof

ActiveCN112877290AIn vitro shape stabilityIn line with clinical tumor biological characteristicsMicrobiological testing/measurementDrug screeningT-lymphoblastic lymphoma/leukemiaCD5
The invention discloses a human T lymphoblastic leukemia / lymphoma cell strain as well as a construction method and an application thereof. The human T lymphoblastic leukemia / lymphoma cell strain is named as human T lymphoblastic leukemia / lymphoma ZYXY-T1, and is preserved in the China Center for Type Culture Collection (Wuhan University, Wuhan, China) on January 20, 2021, and the preservation number is CCTCC NO: C202143. According to the invention, mononuclear cells are extracted and separated from peripheral blood of a clinical human T lymphoblastic leukemia / lymphoma patient, and are subjected to in-vitro culture and continuous natural passage to obtain the T lymphoblastic leukemia / lymphoma protein. The leukemia cell strain has the typical surface antigen expression characteristic of ETP-ALL, namely, the leukemia cell strain does not express CD1alpha, CD5 and CD8, highly expresses a dry line marker CD34, has good in-vitro proliferation capacity and in-vivo tumorigenesis capacity, can be used as a cell material for researching the occurrence and development mechanism of ETP-ALL and individualized treatment in-vitro research, and can be used for in-vivo and in-vitro research of ETP-ALL drug screening, evaluation, and clinical medication.
Owner:ZHEJIANG UNIV

Spleen regulating type B lymphocyte as well as preparation method and application thereof

The invention provides a spleen regulating type B lymphocyte as well as a preparation method and application thereof. On one hand, the invention provides a spleen regulating type B lymphocyte, wherein the proportion of CD1d, CD5 and CD21 / 35 antibody positive regulating type B lymphocytes in the cell is more than 94.6%. The invention further provides a method for preparing the spleen regulating type B lymphocyte. The method for preparing the spleen regulating type B lymphocyte comprises the following steps: taking a spleen cell suspension, and marking with surface antibodies CD1d, CD5 and CD21 / 35; the labeled cells are sorted by fluorescence activated cell sorting. The third aspect of the invention provides application of the spleen regulating type B lymphocyte in preparation of a preparation for targeted colonization in bilateral kidneys. The fourth aspect of the invention provides application of the spleen regulating type B lymphocyte in preparation of a product for kidney protection.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Compositions and methods for the depletion of cd5+ cells

The invention provides anti-CD5 antibodies, antigen-binding fragments thereof, and antibody drug conjugates thereof, for use in treating, for example, a stem cell disorder, cancer, or autoimmune disease, among other hematological and proliferative diseases. Compositions and methods for depleting populations of CD5+ cells, such as CD5+ cancer cells and CD5+ immune cells are described, and can be used to treat cancers and autoimmune diseases directly as stand-alone therapies by eradicating cancerous cells and autoreactive immune cells that express CD5 and / or to prepare a patient for hematopoietic stem cell transplantation, for instance, by depleting populations of CD5+ immune cells that cross-react with, and mount an immune response against, non-self hematopoietic stem cells.
Owner:MAGENTA THERAPEUTICS INC

Method of predicting response of a human subject suffering from multiple sclerosis to interferon beta, (ifn-ß)

InactiveUS20170248617A1Easy and reliable in vitroPeptide/protein ingredientsDisease diagnosisTotal countLymphocyte
The present invention refers to a method of predicting response of a human subject to Interferon beta, (IFN-β), wherein the subject is suffering from Multiple Sclerosis (MS), and wherein the method comprises using, as an indicator, the percentage of CD5+ CD19+ CD45+ B cells over the total count of lymphocytes (CD45+ cells) in a biological sample originating from the human subject and the percentage of CD8+ CD45+ perforin+ T cells over the total count of lymphocytes (CD45+ cells) in a biological sample originating from the human subject, wherein if the percentage of CD5+ CD19+ CD45+ B cells over the total count of lymphocytes (CD45+ cells) is lower than or equal to 3% and / orthe percentage of CD8+ CD45+ perforin+ T cells over the total count of lymphocytes (CD45+ cells) is greater than or equal to 1%, is indicative of response.
Owner:FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVRIO RAMON Y CAJAL

Use of oviductus ranae in preparing medicament for curing and preventing diseases caused by immunologic dysfunction

The invention relates to use of oviductus ranae in preparing medicament for curing and preventing diseases caused by immunologic dysfunction. The flow cytometry and the ELISA method proves that the oviductus ranae has a function for immunity adjustment by the results of mouse spleen T-lymphocyte subsets CD3, CD4, CD5, CD8 and the ratio of CD4 / CD8, namely, when the immunity is high, the oviductus ranae has a function for weakening the immunity, and when the immunity is low, the oviductus ranae has a function for enhancing the immunity. The new use of the oviductus ranae proves that the oviductus ranae has a therapeutical effect for the diseases caused by the immunologic dysfunction such as asthma, autoimmune disease, hepatitis and tumor, thereby developing the use of the oviductus ranae inpreparing medicament for curing and preventing the diseases caused by the immunologic dysfunction.
Owner:CHANGCHUN UNIV OF CHINESE MEDICINE

Use of Anti-cd5 antibody drug conjugate (ADC) in allogeneic cell therapy

The invention provides methods of depleting CD5+ cells in human patients undergoing chimeric antigen receptor (CAR) immunotherapy in order to promote acceptance of CAR expressing immune cells. Anti-CD5 antibody drug conjugates (ADCs) are administered as a conditioning regimen to a human patient receiving autologous or allogeneic CAR expressing immune cells such that the CAR expressing immune cells are accepted by the human patient. Compositions and methods of the invention can be used in combination with CAR therapy to treat a variety of pathologies, including autoimmune diseases and cancer.
Owner:HEIDELBERG PHARMA RES GMBH

Mouse lymphoma cell line and animal model of human high grade b-cell lymphoma

ActiveUS20180255752A1Tumor/cancer cellsAnimal husbandryHigh grade B-cell lymphomaMouse Lymphoma
The invention relates to a new, spontaneous mouse lymphoma cell line displaying CD19, B220, MHC II, surface IgG2a / kappa chain and MAC-1, which is negative for CD5, animal models of B-cell lymphoma based on said cell line and methods for assessing lymphoma propagation and lymphoma expansion based on said cell line.
Owner:PECSI TUDOMANYEGYETEM

Combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia

The invention relates to a combined reagent and system for evaluating the prognosis of chronic lymphocytic leukemia, belonging to the field of medical technology detection. The combination reagent includes at least one of the following antibody combinations: antibody combination 1, including CD5, IgG1, CD3, CD19 and CD45 antibodies; antibody combination 2, including CD5, ZAP70, CD3, CD19 and CD45 antibodies; antibody combination 3: Includes CD38, CD49d, CD19, CD5, and CD45 antibodies. Among the above-mentioned antibody combinations against CLL of the present invention, the expressions of ZAP70, CD38, and CD49d are of great value in evaluating prognosis, and ZAP70 is one of the more accurate ones, but its clinical application is limited due to intracellular staining and gating techniques, and this The invention solves this problem to the greatest extent. In addition, two indicators are added. Combining these markers can provide a more comprehensive assessment of the prognosis of chronic lymphocytic leukemia.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT

T cell depletion therapy

Provided herein are methods of depleting T cells for therapeutic use comprising administering an anti-CD2 or anti-CD5 antibody drug conjugate (ADC) for therapy. Anti-CD2 ADCs or anti-CD5 ADCs are provided for use as agents for the treatment of stem cell disorders, cancer or autoimmune diseases, as well as other hematological and proliferative diseases. The described compositions and methods can be used to deplete a population of CD2 + or CD5 + cells, such as CD2 + or CD5 + cancer cells or CD2 + or CD5 + immune cells, and can also be used to prepare for hematopoietic stem cell transplantation or solid organ transplantation for a patient.
Owner:美真达治疗公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products